Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers

FEBS Open Bio

Volumn 5, Issue , 2015, Pages 542-549

  Oku, Yusuke ^a   Nishiya, Naoyuki ^a   Shito, Toshiya ^a   Yamamoto, Reiichiro ^a   Yamamoto, Yasufumi ^a   Oyama, Chihiro ^a   Uehara, Yoshimasa ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Combination therapy; Dasatinib; Pazopanib; Statins; TAZ; YAP

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; DASATINIB; DOXORUBICIN; FLUINDOSTATIN; ONCOPROTEIN; PACLITAXEL; PAZOPANIB; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TAZ ONCOPROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; YAP ONCOPROTEIN;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; EMBRYO; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 84933512240     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fob.2015.06.007     Document Type: Article

References (40)

1. Mo J.S., Park H.W., Guan K.L. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014, 15(6):642-656.
2. Zhao B., Wei X., Li W., Udan R.S., Yang Q., Kim J., et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007, 21(21):2747-2761.
3. Ota M., Sasaki H. Mammalian tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. Development 2008, 135(24):4059-4069.
4. Kim N.G., Koh E., Chen X., Gumbiner B.M. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc. Natl. Acad. Sci. USA 2011, 108(29):11930-11935.
5. Yu F.X., Zhao B., Panupinthu N., Jewell J.L., Lian I., Wang L.H., et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012, 150(4):780-791.
6. Miller E., Yang J., DeRan M., Wu C., Su A.I., Bonamy G.M., et al. Identification of serum-derived sphingosine-1-phosphate as a small molecule regulator of YAP. Chem. Biol. 2012, 19(8):955-962.
7. Wada K., Itoga K., Okano T., Yonemura S., Sasaki H. Hippo pathway regulation by cell morphology and stress fibers. Development 2011, 138(18):3907-3914.
8. Zhao B., Li L., Wang L., Wang C.Y., Yu J., Guan K.L. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 2012, 26(1):54-68.
9. Bartucci M., Dattilo R., Moriconi C., Pagliuca A., Mottolese M., Federici G., et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 2014.
10. Wang L., Shi S., Guo Z., Zhang X., Han S., Yang A., et al. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One 2013, 8(6):e65539.
11. Noguchi S., Saito A., Horie M., Mikami Y., Suzuki H.I., Morishita Y., et al. An integrative analysis of the tumorigenic role of TAZ in human non-small cell lung cancer. Clin. Cancer Res. 2014.
12. Moeini A., Cornella H., Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer 2012, 1(2):83-93.
13. Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T., et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011, 71(3):873-883.
14. Cordenonsi M., Zanconato F., Azzolin L., Forcato M., Rosato A., Frasson C., et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011, 147(4):759-772.
15. Liu-Chittenden Y., Huang B., Shim J.S., Chen Q., Lee S.J., Anders R.A., et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012, 26(12):1300-1305.
16. Duenas-Gonzalez A., Garcia-Lopez P., Herrera L.A., Medina-Franco J.L., Gonzalez-Fierro A., Candelaria M. The prince and the pauper. A tale of anticancer targeted agents. Mol. Cancer 2008, 7:82.
17. Li Y.Y., Jones S.J. Drug repositioning for personalized medicine. Genome Med. 2012, 4(3):27.
18. Oku Y., Tareyanagi C., Takaya S., Osaka S., Ujiie H., Yoshida K., et al. Multimodal effects of small molecule ROCK and LIMK inhibitors on mitosis, and their implication as anti-leukemia agents. PLoS One 2014, 9(3):e92402.
19. Dupont S., Morsut L., Aragona M., Enzo E., Giulitti S., Cordenonsi M., et al. Role of YAP/TAZ in mechanotransduction. Nature 2011, 474(7350):179-183.
20. Kawada M., Inoue H., Masuda T., Ikeda D. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer. Cancer Res. 2006, 66(8):4419-4425.
21. Calvo F., Ege N., Grande-Garcia A., Hooper S., Jenkins R.P., Chaudhry S.I., et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 2013, 15(6):637-646.
22. Wang Z., Wu Y., Wang H., Zhang Y., Mei L., Fang X., et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc. Natl. Acad. Sci. USA 2013, 111(1):E89-E98.
23. Sorrentino G., Ruggeri N., Specchia V., Cordenonsi M., Mano M., Dupont S., et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol. 2014, 16(4):357-366.
24. Bryan B.A., Dennstedt E., Mitchell D.C., Walshe T.E., Noma K., Loureiro R., et al. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 2010, 24(9):3186-3195.
25. He M., Cheng Y., Li W., Liu Q., Liu J., Huang J., et al. Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. BMC Cancer 2010, 10:170.
26. Pertz O., Hodgson L., Klemke R.L., Hahn K.M. Spatiotemporal dynamics of RhoA activity in migrating cells. Nature 2006, 440(7087):1069-1072.
27. Timoshenko A.V., Rastogi S., Lala P.K. Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br. J. Cancer 2007, 97(8):1090-1098.
28. Jechlinger M., Sommer A., Moriggl R., Seither P., Kraut N., Capodiecci P., et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Investig. 2006, 116(6):1561-1570.
29. Zhao B., Li L., Tumaneng K., Wang C.Y., Guan K.L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 2010, 24(1):72-85.
30. Chen Q., Zhang N., Gray R.S., Li H., Ewald A.J., Zahnow C.A., et al. A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev. 2014, 28(5):432-437.
31. Chen D., Sun Y., Wei Y., Zhang P., Rezaeian A.H., Teruya-Feldstein J., et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat. Med. 2012, 18(10):1511-1517.
32. Lai D., Ho K.C., Hao Y., Yang X. Taxol resistance in breast cancer cells is mediated by the Hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 2011, 71(7):2728-2738.
33. Knecht D.A., LaFleur R.A., Kahsai A.W., Argueta C.E., Beshir A.B., Fenteany G. Cucurbitacin I inhibits cell motility by indirectly interfering with actin dynamics. PLoS One 2010, 5(11):e14039.
34. Price D.J., Miralem T., Jiang S., Steinberg R., Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. 2001, 12(3):129-135.
35. Yu Y.C., Yang P.M., Chuah Q.Y., Huang Y.H., Peng C.W., Lee Y.J., et al. Radiation-induced senescence in securin-deficient cancer cells promotes cell invasion involving the IL-6/STAT3 and PDGF-BB/PDGFR pathways. Sci. Rep. 2013, 3:1675.
36. Bachelder R.E., Wendt M.A., Mercurio A.M. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 2002, 62(24):7203-7206.
37. Yoshiji H., Gomez D.E., Shibuya M., Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 1996, 56(9):2013-2016.
38. Bryan B.A., Dennstedt E., Mitchell D.C., Walshe T.E., Noma K., Loureiro R., et al. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 2010, 24(9):3186-3195.
39. Yuen H.F., McCrudden C.M., Huang Y.H., Tham J.M., Zhang X., Zeng Q., et al. TAZ expression as a prognostic indicator in colorectal cancer. PLoS One 2013, 8(1):e54211.
40. Touil Y., Igoudjil W., Corvaisier M., Dessein A.F., Vandomme J., Monte D., et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin. Cancer Res. 2014, 20(4):837-846.